CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

• Main Authors: E. I. Alexeeva (Author), R. V. Denisova (Author), T. V. Sleptsova (Author), T. M. Bzarova (Author), K. B. Isaeva (Author), E. V. Mitenko (Author), E. G. Chistyakova (Author), A. M. Chomakhidze (Author), N. I. Taybulatov (Author), A. N. Fetisova (Author), O. L. Lomakina (Author), S. I. Valieva (Author)
• Format: Book
• Published: Union of pediatricians of Russia, 2014-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinuma...